Rare disease

#Biotherapeutics #Clinical trials #Drug development #Drug discovery #Pharma #Rare disease

This week in drug discovery (19 – 23 July)

News round-up by DDW’s Megan Thomas for 19 – 23 July DDW’s Megan Thomas rounds up her top five stories this week which facilitate the continuation of vital drug discovery research, from partnerships and funding to successful trials and informative reports. Exscientia accelerates Covid-19 drug discovery using AI Exscientia… Read More

#News #Trending News

#Biotherapeutics #Clinical trials #Drug development #Drug discovery #Pharma #Rare disease

This week in drug discovery (5 – 9 July)

News round-up by DDW’s Megan Thomas for 5 – 9 July We know that innovation is key in the drug discovery and development sector. DDW’s Megan Thomas rounds up her top five stories this week which highlight the industry’s on-going work to create breakthrough therapeutics for global wellbeing. Read More

#News #Trending News

#Immunodeficiency #Immunotherapy #Rare disease

Restoring immune function in children with rare immunodeficiency

An investigational gene therapy can safely restore the immune systems of infants and children who have a rare, life-threatening inherited immunodeficiency disorder, according to research supported in part by the National Institutes of Health (NIH). The researchers found that 48 of 50 children who received the gene therapy retained their… Read More

#News

#Drug delivery #Drug development #Rare disease

Sanofi makes access to essential medicines commitment

Sanofi CEO Paul Hudson has outlined key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy. The company’s commitment is based on: access to medicines, support for vulnerable communities, preservation of the environment, and inclusion and diversity of its employees. “The pandemic… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trials #Drug discovery #Pharmaceuticals #Rare disease #Therapeutics

The move towards patient-powered, data-driven rare disease drug discovery

By Rayne Rodgers, Vice President and Executive Director of MOVR for Muscular Dystrophy Association (MDA), and Sharon Hesterlee MDA’s Executive Vice President and Chief Research Officer. As an umbrella organisation representing those living with more than 40 types of neuromuscular disorders, the Muscular Dystrophy Association (MDA) contributes significantly to innovations… Read More

#Editor's Choice #Exclusive Content #News